Form 4 for RCUS Arcus Biosciences, Inc.
Accepted 2024-01-25 00:00:00 ET · period of report 2024-01-23 · accession 0001724521-24-000024 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-25 | 2024-01-23 | RCUS | Nuyten Dimitry SA | Chief Medical Off | A - Grant | $0.00 | +28.0K | 99.2K | +39% | $0 |
| D | 2024-01-25 | 2024-01-23 | RCUS | Nuyten Dimitry SA | Chief Medical Off | A - Grant | $0.00 | +113.7K | 113.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-23 | A | A | 28,000 | $0.00 | 99,195 | D | — | — | (F1) Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2024, subject to the Reporting Person's continued service to the Company. |
| 2 | Derivative | Stock Option (right to buy) | 2024-01-23 | A | A | 113,700 | $0.00 | 113,700 | D | $15.44 · — to 2034-01-22 | 113,700 Common Stock | (F2) The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company. |